After full approval, Sarepta lays out its next moves

Sarepta Therapeutics reached a major milestone last week as the FDA granted full approval for its Duchenne muscular dystrophy gene therapy Elevidys to be used in ambulatory patients at least 4 years old with a confirmed mutation in the DMD gene. The regulator also granted accelerated approval to patients who can’t walk.